Baird analyst David Rescott raised the firm’s price target on Haemonetics (HAE) to $82 from $65 and keeps an Outperform rating on the shares.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
- Haemonetics Reports Improved Profitability Amid Revenue Decline
- Haemonetics: Strong Financial Performance and Strategic Adjustments Drive Buy Rating
- Haemonetics price target raised to $88 from $85 at BTIG
- Haemonetics rises 26.1%
- Haemonetics narrows FY26 adjusted EPS view to $4.80-$5.00 from $4.70-$5.00